Some interesting articles relating to the African setting have been published in the latest issue of GJMEDPH.
HIV self-testing is a way to reach more people with undiagnosed HIV and represents a step forward to empower individuals, diagnose people earlier before they become sick, bring services closer to where people live, and create demand for HIV testing.
The third annual South African Stock Outs National Survey finds lack of consistent improvement in decreasing medication stock outs in public health care facilities around the country. Results vary by province and specific medications.
Several African countries have contributed in the numerous HIV related clinical trials which have been conducted to provide the highest-quality scientific evidence. Many effective therapies and interventions have been developed such as antiretroviral drugs, pre-exposure prophylaxis, topical microbicides and HIV vaccines.
On May 18th, 2016, The National Institute of Health and Infectious Diseases (NIAID) announced a new clinical trial called HVTN702. The trial is set to begin November 2016 at 15 South African sites. It will enroll 5,400 HIV-uninfected adults aged 18-35.
United Nations General Assembly (UNGASS) happening now on global drug policy. Wilson Box from the Vienna Committee on drugs shares insights from New York.
While the drive to increase coverage to ART needs to continue, there is also an urgent need for policymakers and healthcare providers to focus beyond the goal of prolonging survival and to concentrate ensuring that adolescents living with HIV achieve an optimum quality of life.